Sequence variations in HIV-1 p24 Gag-derived epitopes can alter binding of KIR2DL2 to HLA-C*03: 04 and modulate primary natural killer cell function

AIDS

Volumn 28, Issue 10, 2014, Pages 1399-1408

  Van Teijlingen, Nienke H ^a,b   Hölzemer, Angelique ^a   Körner, Christian ^a   García Beltrán, Wilfredo F ^a   Schafer, Jamie L ^c   Fadda, Lena ^a   Suscovich, Todd J ^a   Brander, Christian ^d   Carrington, Mary ^a,e   Evans, David T ^c,f   Van Baarle, Debbie ^g,h   Altfeld, Marcus ^a,i  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b ACADEMIC MEDICAL CENTER   (Netherlands)

^c HARVARD MEDICAL SCHOOL   (United States)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e SAIC FREDERICK INC   (United States)

^f UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^g UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^h NATIONAL INSTITUTE FOR PUBLIC HEALTH AND THE ENVIRONMENT   (Netherlands)

ⁱ LEIBNIZ INSTITUTE FOR EXPERIMENTAL VIROLOGY   (Germany)

Author keywords

HIV 1 epitopes; Innate immunity; Killer cell immunoglobulin like receptor; Natural killer cell

Indexed keywords

EPITOPE; GAG PROTEIN; HLA C ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; NATURAL KILLER CELL RECEPTOR; HLA-C*03:04 ANTIGEN; KIR2DL2 PROTEIN, HUMAN; PROTEIN BINDING;

AMINO ACID SEQUENCE; ARTICLE; CELL FUNCTION; DEGRANULATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; NATURAL KILLER CELL; POINT MUTATION; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; CELL LINE; GENETIC VARIABILITY; GENETICS; IMMUNOLOGY; METABOLISM;

CELL DEGRANULATION; CELL LINE; EPITOPES; GENETIC VARIATION; HIV CORE PROTEIN P24; HLA-C ANTIGENS; HUMANS; KILLER CELLS, NATURAL; PROTEIN BINDING; RECEPTORS, KIR2DL2;

EID: 84902275073     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000284     Document Type: Article

References (44)

1. Cooper MA, Fehniger TA, Fuchs A, Colonna M, Caligiuri MA. NK cell and DC interactions. Trends Immunol 2004; 25:47-52.
2. Andrews DM, Estcourt MJ, Andoniou CE, Wikstrom ME, Khong A, Voigt V, et al. Innate immunity defines the capacity of antiviral T cells to limit persistent infection. J Exp Med 2010; 207:1333-1343.
3. Waggoner SN, Cornberg M, Selin LK, Welsh RM. Natural killer cells act as rheostats modulating antiviral T cells. Nature 2011; 481:394-398.
4. Jost S, Altfeld M. Control of human viral infections by natural killer cells. Annu Rev Immunol 2013; 31:163-194.
5. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert JJ, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Genet 2002; 31:429-434.
6. Martin MP, Qi Y, Gao X, Yamada E, Martin JN, Pereyra F, et al. Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat Genet 2007; 39:733-740.
7. Alter G, Rihn S, Walter K, Nolting A, Martin M, Rosenberg ES, et al. HLA class I subtype-dependent expansion of KIR3DS1R and KIR3DL1R NK cells during acute human immunodeficiency virus type 1 infection. J Virol 2009; 83:6798-6805.
8. Long BR, Ndhlovu LC, Oksenberg JR, Lanier LL, Hecht FM, Nixon DF, et al. Conferral of enhanced natural killer cell function by KIR3DS1 in early human immunodeficiency virus type 1 infection. J Virol 2008; 82:4785-4792.
9. Alter G, Martin MP, Teigen N, Carr WH, Suscovich TJ, Schneidewind A, et al. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med 2007; 204:3027-3036.
10. Boyington JC, Motyka SA, Schuck P, Brooks AG, Sun PD. Crystal structure of an NK cell immunoglobulin-like receptor in complex with its class I MHC ligand. Nature 2000; 405:537-543.
11. Fan QR, Long EO, Wiley DC. Crystal structure of the human natural killer cell inhibitory receptor KIR2DL1-HLA-Cw4 complex. Nat Immunol 2001; 2:452-460.
12. Saulquin X, Gastinel LN, Vivier E. Crystal structure of the human natural killer cell activating receptor KIR2DS2 (CD158j). J Exp Med 2003; 197:933-938.
13. Stewart-Jones GB, di Gleria K, Kollnberger S, McMichael AJ, Jones EY, Bowness P. Crystal structures and KIR3DL1 recognition of three immunodominant viral peptides complexed to HLA-BM2705. Eur J Immunol 2005; 35:341-351.
14. Vivian JP, Duncan RC, Berry R, O'Connor GM, Reid HH, Beddoe T, et al. Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen B. Nature 2011; 479:401-405.
15. Malnati MS, Peruzzi M, Parker KC, Biddison WE, Ciccone E, Moretta A, et al. Peptide specificity in the recognition of MHC class I by natural killer cell clones. Science 1995; 267:1016-1018.
16. Peruzzi M, Wagtmann N, Long EO. A p70 killer cell inhibitory receptor specific for several HLA-B allotypes discriminates among peptides bound to HLA-BM2705. J Exp Med 1996; 184:1585-1590.
17. Mandelboim O, Wilson SB, Vales-Gomez M, Reyburn HT, Strominger JL. Self and viral peptides can initiate lysis by autologous natural killer cells. Proc Natl Acad Sci U S A 1997; 94:4604-4609.
18. Rajagopalan S, Long EO. The direct binding of a p58 killer cell inhibitory receptor to human histocompatibility leukocyte antigen (HLA)-Cw4 exhibits peptide selectivity. J Exp Med 1997; 185:1523-1528.
19. Zappacosta F, Borrego F, Brooks AG, Parker KC, Coligan JE. Peptides isolated from HLA-CwM0304 confer different degrees of protection from natural killer cell-mediated lysis. Proc Natl Acad Sci U S A 1997; 94:6313-6318.
20. Vales-Gomez M, Reyburn HT, Erskine RA, Strominger J. Differential binding to HLA-C of p50-activating and p58-inhibitory natural killer cell receptors. Proc Natl Acad Sci U S A 1998; 95:14326-14331.
21. Maenaka K, Juji T, Nakayama T, Wyer JR, Gao GF, Maenaka T, et al. Killer cell immunoglobulin receptors and T cell receptors bind peptide-major histocompatibility complex class I with distinct thermodynamic and kinetic properties. J Biol Chem 1999; 274:28329-28334.
22. Hansasuta P, Dong T, Thananchai H, Weekes M, Willberg C, Aldemir H, et al. Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific. Eur J Immunol 2004; 34:1673-1679.
23. Stewart CA, Laugier-Anfossi F, Vely F, Saulquin X, Riedmuller J, Tisserant A, et al. Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors. Proc Natl Acad Sci U S A 2005; 102:13224-13229.
24. Thananchai H, Gillespie G, Martin MP, Bashirova A, Yawata N, Yawata M, et al. Cutting Edge: Allele-specific and peptidedependent interactions between KIR3DL1 and HLA-A and HLA-B. J Immunol 2007; 178:33-37.
25. Fadda L, Borhis G, Ahmed P, Cheent K, Pageon SV, Cazaly A, et al. Peptide antagonism as a mechanism for NK cell activation. Proc Natl Acad Sci U S A 2010; 107:10160-10165.
26. Fadda L, Korner C, Kumar S, van Teijlingen NH, Piechocka- Trocha A, Carrington M, et al. HLA-CwM0102-restricted HIV-1 p24 epitope variants can modulate the binding of the inhibitory KIR2DL2 receptor and primary NK cell function. PLoS Pathog 2012; 8:e1002805.
27. Norman PJ, Stephens HA, Verity DH, Chandanayingyong D, Vaughan RW. Distribution of natural killer cell immunoglobulin- like receptor sequences in three ethnic groups. Immunogenetics 2001; 52:195-205.
28. Cohen GB, Gandhi RT, Davis DM, Mandelboim O, Chen BK, Strominger JL, et al. The selective downregulation of class I major histocompatibility complex proteins by HIV-1 protects HIV-infected cells from NK cells. Immunity 1999; 10:661-671.
29. Fellay J, Shianna KV, Ge D, Colombo S, Ledergerber B, Weale M, et al. A whole-genome association study of major determinants for host control of HIV-1. Science 2007; 317:944-947.
30. International HIV Controllers Study. Pereyra F, Jia X, McLaren PJ, Telenti A, de Bakker PI, Walker BD, et al. The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 2010; 330:1551-1557.
31. Apps R, Qi Y, Carlson JM, Chen H, Gao X, Thomas R, et al. Influence of HLA-C expression level on HIV control. Science 2013; 340:87-91.
32. Kamya P, Boulet S, Tsoukas CM, Routy JP, Thomas R, Cote P, et al. Receptor-ligand requirements for increased NK cell polyfunctional potential in slow progressors infected with HIV-1 coexpressing KIR3DL1Mh/My and HLA-BM57. J Virol 2011; 85:5949-5960.
33. Greenwood R, Shimizu Y, Sekhon GS, DeMars R. Novel allelespecific, posttranslational reduction in HLA class I surface expression in a mutant human B cell line. J Immunol 1994; 153:5525-5536.
34. Braud VM, Allan DS, Wilson D, McMichael AJ. TAP- and tapasin-dependent HLA-E surface expression correlates with the binding of an MHC class I leader peptide. Curr Biol 1998; 8:1-10.
35. Littaua RA, Oldstone MB, Takeda A, Debouck C, Wong JT, Tuazon CU, et al. An HLA-C-restricted CD8R cytotoxic T-lymphocyte clone recognizes a highly conserved epitope on human immunodeficiency virus type 1 gag. J Virol 1991; 65:4051-4056.
36. Kaul R, Dong T, Plummer FA, Kimani J, Rostron T, Kiama P, et al. CD8R lymphocytes respond to different HIV epitopes in seronegative and infected subjects. J Clin Invest 2001; 107:1303-1310.
37. Daucher M, Price DA, Brenchley JM, Lamoreaux L, Metcalf JA, Rehm C, et al. Virological outcome after structured interruption of antiretroviral therapy for human immunodeficiency virus infection is associated with the functional profile of virus-specific CD8R T cells. J Virol 2008; 82:4102-4114.
38. Kiepiela P, Leslie AJ, Honeyborne I, Ramduth D, Thobakgale C, Chetty S, et al. Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature 2004; 432:769-775.
39. Currier JR, Visawapoka U, Tovanabutra S, Mason CJ, Birx DL, McCutchan FE, et al. CTL epitope distribution patterns in the Gag and Nef proteins of HIV-1 from subtype A infected subjects in Kenya: use of multiple peptide sets increases the detectable breadth of the CTL response. BMC Immunol 2006; 7:8.
40. Kiepiela P, Ngumbela K, Thobakgale C, Ramduth D, Honeyborne I, Moodley E, et al. CD8R T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007; 13:46-53.
41. Day CL, Kiepiela P, Leslie AJ, van der Stok M, Nair K, Ismail N, et al. Proliferative capacity of epitope-specific CD8 T-cell responses is inversely related to viral load in chronic human immunodeficiency virus type 1 infection. J Virol 2007; 81:434-438.
42. Honeyborne I, Codoner FM, Leslie A, Tudor-Williams G, Luzzi G, Ndung'u T, et al. HLA-CwM03-restricted CD8R T-cell responses targeting the HIV-1 gag major homology region drive virus immune escape and fitness constraints compensated for by intracodon variation. J Virol 2010; 84:11279-11288.
43. Masemola AM, Mashishi TN, Khoury G, Bredell H, Paximadis M, Mathebula T, et al. Novel and promiscuous CTL epitopes in conserved regions of Gag targeted by individuals with early subtype C HIV type 1 infection from southern Africa. J Immunol 2004; 173:4607-4617.
44. Alter G, Heckerman D, Schneidewind A, Fadda L, Kadie CM, Carlson JM, et al. HIV-1 adaptation to NK-cell-mediated immune pressure. Nature 2011; 476:96-100.